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REVIEWCURRENTOPINION Genetic testing in children and adolescents
with intellectual disability Copyright 
www.co-psychiatry.coma bNick Bass and David SkusePurpose of review
Investigation for genetic causes of intellectual disability has advanced rapidly in recent years. We review
the assessment of copy number variants (CNVs) and the use of next-generation sequencing based assays to
identify single nucleotide variation in intellectual disability. We discuss the diagnostic yields that can be
expected with the different assays. There is high co-morbidity of intellectual disability and psychiatric
disorders. We review the relationship between variants which are pathogenic for intellectual disability and
the risk of child and adolescent onset psychiatric disorders.
Recent findings
The diagnostic yields from genome wide CNV analysis and whole exome sequence analysis are high – in
the region of 15 and 40%, respectively – but vary according to exact referral criteria. Many variants
pathogenic for intellectual disability, notably certain recurrent CNVs, have emerged as strong risk factors
for other neurodevelopmental disorders such as autism spectrum disorders, attention deficit hyperactivity
disorder, and schizophrenia.
Summary
It is now conceivable that etiological variants could be identified in the majority of children presenting with
intellectual disability using next-generation sequencing based assays. However, challenges remain in
assessment of the pathogenicity of variants, reporting of incidental findings in children and determination
of prognosis, particularly in relation to psychiatric disorders.
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Half of all mental health problems encountered in
adulthood have already been established by the age
of 14, and up to 75% by age 24 [1]. Ten percent of
children aged 5–16 years have a diagnosable prob-
lem such as conduct disorder, anxiety disorder,
attention deficit hyperactivity disorder (ADHD),
or depression [2]. These figures are substantially
higher in children with intellectual disability [3].
DSM-5 [4] defines intellectual disability as a disorder
with onset during the developmental period that
adversely affects both intellectual and adaptive
functioning, causing deficits in conceptual, social,
and practical domains. Mild, moderate, severe, and
profound degrees of disability are defined on the
basis of adaptive functioning nowadays, rather than
in terms of IQ test results. This is because every day
reasoning and judgment-making by people with
intellectual disability is often poorer than formal
cognitive assessments imply. In the United King-
dom, the management of people with intellectual© 2018 Wolters Kluwer disability is led by local specialist learning disability
services, if these are available.
In most cases, the cause of intellectual disability
is unknown, especially in people who have a non-
syndromic condition that lacks physical signs.
Genomic variation is probably the leading cause
of mild intellectual impairment in the general pop-
ulation. We each possess around 3million polymor-
phic nucleotide variants in our genomes, the great
majority of which are ‘common’ in the sense that weHealth, Inc. All rights reserved.
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KEY POINTS
 CMA detects pathogenic variants in approximately
15% of children with developmental delay.
 WES may detect pathogenic variants in more 50% of
children with developmental delay if used as a first tier
diagnostic test and where parents are available
for genotyping.
 Some variants pathogenic for intellectual disability,
particularly CNVs, are strong risk factors for other
neurodevelopmental disorders such as schizophrenia,
ADHD and ASD.
 There is a paucity of information about specific
associations of childhood onset psychiatric disorders
with more recently identified variants pathogenic for
intellectual disability.
 Systematic psychiatric phenotyping in genomic
intellectual disability disorders is important to inform
prognosis and facilitate early intervention.
Children and adolescents with intellectual disability Bass and Skuseshare those variants with a substantial minority of
other healthy individuals. These are often called
single nucleotide polymorphisms (SNPs), defined
as genomic differences in a single nucleotide, at a
particular position in the genome where such varia-
tion is not rare. The cumulative impact of such
variants, which occur in over 90% of all human
genes, accounts for individual differences in com-
plex physical and cognitive characteristics such as
height and general intelligence. Most mild intellec-
tual disability is probably attributable to common
variation. Polygenic variation is also thought to
contribute most genetic risk to the development
of autism spectrum disorders (ASDs) [5].
A small proportion of such variants are unique,
or almost unique to us as individuals (although they
may also be found in our blood relatives). These are
often known as privatemutations, or as single nucle-
otide variants (SNVs). If they occur in a protein
coding or regulatory part of a gene, they may alter
genetic function if they are nonsynonymous with
the typical nucleotide at that position. SNVs that
arise in the germline of egg or sperm are termed ‘de
novo’. Disruptive SNVs are often associated with
rare syndromes, and in a substantial proportion of
such syndromes there is associated intellectual dis-
ability [6,7]. De-novo SNVs are thought to be
responsible for most severe and profound intellec-
tual disability [8], because affected individuals are
unlikely to reproduce (and therefore do not pass on
the mutation to future generations). SNVs in over
700 genes have been identified as contributing
to autosomal dominant, autosomal recessive, and Copyright © 2018 Wolters Kluwe
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sequencing (WES) can detect de-novo coding muta-
tions if they occur within genes, but many SNVs are
in intergenic regions, hence are not picked up by
this technique. Whole genome sequencing (WGS)
has the capacity to identify rare variants in the
regions between genes too and is reported to find
coding mutations and potentially pathogenic struc-
tural changes in up to 60% of severe/profound
intellectual disability cases. However, the interpre-
tation of WGS-identified noncoding (intergenic)
variants is problematic because we know relatively
little about their impact on gene regulation [7].
Another class of genetic anomaly is responsible
for many cases of intellectual disability. Copy-
number variants (CNVs) are structural changes in
the genome that may duplicate or delete a segment
of DNA. Such CNVs may be inherited or they may
arise de novo, and they are usually between 15kb and
1 Mb in length. They contribute to a range of neuro-
developmental disorders in both childhood [10] and
adulthood [11
&&
]. Not all CNVs are pathogenic [12],
but pathogenic CNV are found in up to 15% of
children referred for genetic investigation of develop-
mental delay [13]. Some CNVs are particularly
strongly associated with intellectual disability [14],
especially themilder forms, and these are often famil-
ial. Recent research has shown, in both European and
North American general population cohorts, that
deletions of medium size and large duplications of
DNAhave a small butmeasurable detrimental impact
on the IQ, and educational achievement, of people
who possess them. The explanation is thought to be
that large CNVs disrupt the action of many genes
within the affected region, and the detriment to




].GENETIC TESTING IN INTELLECTUAL
DISABILITY
Chromosomal microarray analysis (CMA) encom-
pass all types of array-based genomic analyses,
including array-based comparative genomic hybrid-
ization (aCGH) and SNP arrays. To identify poten-
tially pathogenic CNVs, DNA testing with aCGH is
often the first-line diagnostic test for children with
intellectual disability, in both Europe and North
America [18,19
&
,20]. The introduction of array-based
copy-number analysis has led to the identification of
both inherited and de-novo microdeletions and
duplications inup to15%of cases [21]. It is important
to be aware that the attribution of pathogenicity to a
CNV identified by a microarray is by no means
straightforward, and there is no universally agreed
standard in the United Kingdom. Many CNVs are
excessively rare events, and conclusions regardingr Health, Inc. All rights reserved.
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Child and adolescent psyhciatrythe apparent strength of their association with cog-
nition and psychiatric risk are therefore critically
dependent on the interpretation of genomic data
from unaffected comparison populations. In that
regard, some variants previously considered to be
pathogenic are being re-evaluated in light of increas-
ing knowledge regarding their lack of association
with disease in the general population.
WES is not routinely available in the UK’s
National Health Service, but some Regional Genet-
ics Centres are using specialist panel arrays to detect
small nucleotide variants that are known to be
associated with intellectual disability and other dis-
orders of neurodevelopment. The proportion of
sporadic cases of intellectual disability caused by
point mutations (SNV) is unknown. Exome
sequencing has led to an increasing identification
of de-novo variants [22], but in clinical practice,
because of high locus heterogeneity, we often can-
not with confidence attribute pathogenicity to indi-
vidual mutations [8]. Evidence to guide such
decision-making is slowly emerging from two recent
UK national research studies that have recruited
children with intellectual disability, of probable
genetic etiology. The Deciphering Developmental
Disorders (DDD) project employed genome-wide
microarray and WES in a nationwide survey of chil-
dren with complex developmental disorders of
probable genetic origin [23
&&
]. Damaging de-novo
coding mutations were found in 42% of these pre-
viously investigated, yet undiagnosed, children, the
vast majority (90%) of whom had associated intel-
lectual disability. Themore recent 100 000Genomes
project has usedWGS to investigate a similar cohort,
but the results are as yet unpublished [24].WHO GETS TESTED?
A recent review, summarizing the outcome of sev-
eral years of genetic testing for intellectual disability
by a London community paediatric clinic [25
&
],
stated referrals had been made by a wide range of
paediatric specialists, general practitioners, thera-
pists, and schools. Practitioners called for genetic
testing when they predicted it was likely to be of
diagnostic value, based on criteria that included
significant developmental delay, an unusual physi-
cal phenotype, epilepsy and parental consanguinity.
Rarely, if ever, was the reason for genetic testing in
intellectual disability prompted by a neurodevelop-
mental disorder that manifested in terms of behav-
ior. If a genetic diagnosis is made following CMA
investigation, this may lead to counseling about the
likely prognosis or potential complications associ-
ated with the disorder [26
&
]. A positive genetic find-
ing in association with intellectual disability can Copyright © 2018 Wolters Kluwer 
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future children, following cascade testing of biologi-
cal relatives. It is important to be aware that CMA
testing is not without drawbacks. In addition to
the challenges of determining the pathogenicity of
many variants that could have contributed to the
neurodevelopmental disability, there is the ethical
dilemma of reporting incidental findings to the fam-
ily of the affected child. Such incidental findings
could include thediscoveryof risk variants for serious
adult-onset diseases, such as breast cancer. Genetic
testing of children with intellectual disability is now-
adays focused on the preschool population, whereas
most child psychiatry services do not routinely assess
children under 6 years of age. However, a recent
survey of child and intellectual disability psychia-
trists in the United Kingdom found that just over
half had directly ordered genetic investigations at
some time. Although the majority of psychiatrists
thought genetic diagnosis was helpful for the family,
the responses suggested that the diagnosis did not
often result in management changes [27
&
].GENETIC CAUSES OF ID AND RISK OF
PSYCHIATRIC DISORDERS
A broad range of childhood-onset psychiatric disor-
ders is found in associationwith intellectual disability
[28,29], but there is rarely any evidence of a specific
genetic cause, with the exception of some cases of
ASD. In adults with intellectual disability, there is a
better understandingof the risks of psychiatric comor-
bidity in those bearing some rare genetic anomalies
[30
&
], such as a few well studied pathogenic CNVs,
including schizophrenia’s associationwith 22q11.2 or
1q21.1microdeletions [31].Thereason for thispaucity
of knowledge is partly because the focus of previous
research in children with intellectual disability has
been on individuals with a small range of conditions,
especially ASD [32
&
] and ADHD [33
&
], who are then
subject to genetic screening. If damaging variants are
found that are excessively rare in controls, there is a
tendency to assume specificity. But because of high
locusheterogeneity, it ishard todrawfirmconclusions
about the specific psychiatric pathogenicity of indi-
vidual mutations [8]; mutations in genes associated
with intellectual disability cause a wide range of phe-
notypes [34]. The alternative approach, undertaking
broad psychiatric phenotyping of a representative
sample of children with intellectual disability who
have pathogenic genetic anomalies, is essential in
order to set existing findings in context.
An excess of males is ascertained with neuro-
developmental disorders, including intellectual dis-
ability. The reasons for this bias is not known, but it
is apparently not attributable to X-linked variantsHealth, Inc. All rights reserved.
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accounts for no more than 8% or so of male cases
[35], and awide range of epidemiological studies has
shown that the excess of males over females is up to
50%. This observation has been linked to the theory
that for females, at genetic risk, to manifest the
phenotype of neurodevelopmental dysfunction
they need to possess higher mutational burden than
males [36]. The phenomenon has been termed the
female protective effect [37]. We know that males
with normal-range IQ are more likely to be referred
for genetic testing than females carrying the same
autosomal variant, in populations with ASD. In the
Simons Simplex Collection (SSC) of individuals with
ASD, rare truncating SNVs show a slight female
excess [38], but there are significantly more females
than males with large (more than 400kb) CNVs.
Where the CNV was familial, maternal transmission
was significantly higher than paternal transmission
for these large deleterious CNVs. This contrasts with
evidence that the rate of de-novo point mutations is
generally increased among older fathers [39].GENETIC TESTING IN INTELLECTUAL
DISABILITY AND AUTISM SPECTRUM
DISORDERS
NICE guidelines in the United Kingdom [40] do not
recommend routine genetic tests for children with
an autistic disorder, but states these will be done ‘as
recommended by your regional genetics center, if
there are specific dysmorphic features, congenital
anomalies and/or evidence of a learning (intellec-
tual) disability’. It used to be thought that children
with autistic disorders were usually developmen-
tally delayed. In a sense that is true, insofar as there
is a substantially increased risk of ASD in children
with intellectual disability [3], and consequently the
apparent population prevalence of ASD is influ-
enced by the prevalence of intellectual disability.
In the United States, the 2014 National Health
Interview Survey of Autism [41] used a revised ques-
tion ordering and a new approach that asked about
autistic characteristics before developmental dis-
abilities. This change resulted in substantial
increases in the apparent prevalence of autistic dis-
orders because children formerly assigned as devel-
opmental disabilities were designated as having a
primary diagnosis of ASD instead.
At a population level, most newly diagnosed
autism is not nowadays associated with generalized
learning disabilities, probably because the clinical
ascertainment of autistic features in children of
normal range intelligence has improved in recent
years [42
&
]. The heritability of autism is very high
[43
&
] implying shared, familial genetic risk factors Copyright © 2018 Wolters Kluwe
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a population level is because of common variation,
but this acts additively with rare variation to
enhance risk in those ASD cases who carry a strongly
acting de-novo variant [44
&
]. A recent review of
genetic risk in autism [45
&
] emphasized that CNVs
that are associated with a high risk of autism overlap
with those known to cause intellectual disability.Not
only are they expressed in the brain but are especially
likely to involve genes that are structurally or func-
tionally engaged in chromatin remodeling and tran-
scription regulation. CNVs that are particularly
strongly associated with ASD include duplications
of 16p11.2, deletions of 15q13.3, 2p16.3, and
15q11.2 [46]. The yield of genetic testing of non-
syndromal cases of autism in simplex families (which
are less likely than multiplex families to carry herita-
ble private mutations) can be estimated from inter-
nationally curated samples. Large structural
abnormalities (CNVs),whicharedetectablebymicro-
array, can be found in up to 10% of cases [32
&
]. These
CNVs are usually associated with relatively mild
learning disabilities, and they comprise both inher-
ited and de-novo anomalies. The wider use of exome
sequencing is likely to increase the proportion of
cases with an identifiable point mutation or indels
that are the cause of loss of function or otherwise
disrupting, the great majority of which are de novo
(and likely to be paternal in origin [47]).CONCLUSION AND FUTURE DIRECTIONS
In summary, when applied as a first-tier test for
broadly defined developmental delay, current
widely-available arrays (aCGH) detect pathogenic
variants in approximately 15%of children.We know
that, in a research context, WES gives a greater diag-
nostic yield of around 40% in children with severe
developmental delay and it is estimated that yield
could exceed 50% if used as a first tier diagnostic test
[48
&&
]. We anticipate that WGS may provide even
better identification of pathogenic variants,
although there is still debate about the interpretation
of intergenic SNV. However, accurate assignment of
pathogenicity to SNV is getting better, prompting





]. Economic analysis suggests that current
use of WES reduces healthcare costs when applied to
the investigation of intellectual disability [50
&
].
The falling cost of WGS, and the associated
improvement in our ability to detect very small
CNVs, makes it likely that the first-tier investigation
of childhood intellectual disability will be WGS-
based in the future. However, our understanding
of the relationship between genotype and
phenotype in intellectual disability and relatedr Health, Inc. All rights reserved.
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Child and adolescent psyhciatryneurodevelopmental disorders is at an early stage for
the majority of variants. Epigenetic changes are also
likely to have important modifying effect on these
neurodevelopmental trajectories, but measurement
of epigenetic changes and integration of this infor-
mation and polygenic risk for prognostic predica-
tion represents a significant research challenge.
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